At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ITRM Iterum Therapeutics Plc
Closed Good Friday 04-17 16:00:00 EDT
1.08
+0.03
+2.86%
盘后1.05
-0.03-2.78%
18:23 EDT
| High1.10 | Low1.05 | Vol215.60K |
| Open1.05 | D1 Closing1.05 | Amplitude4.76% |
| Mkt Cap37.35M | Tradable Cap36.54M | Total Shares34.58M |
| T/O234.34K | T/O Rate0.64% | Tradable Shares33.84M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics
GlobeNewswire · 04-14
Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ...
GuruFocus.com · 02-08
Iterum Therapeutics Faces Commercialization Challenges for ORLYNVAH™ Despite FDA Approval
TIPRANKS · 02-08
Q4 2024 Iterum Therapeutics PLC Earnings Call
Thomson Reuters StreetEvents · 02-08
BRIEF-Iterum Therapeutics PLC Files For Mixed Shelf Of Up To $150 Million
Reuters · 02-07
Iterum Therapeutics files $150M mixed securities shelf
TIPRANKS · 02-07
Iterum Therapeutics PLC reports results for the quarter ended December 31 - Earnings Summary
Reuters · 02-07
Iterum Therapeutics Q4 2024 Adj EPS $(0.12) Beats $(0.21) Estimate
Benzinga · 02-07
Iterum Therapeutics Q4 Adjusted Net Income USD -3.14 Million
THOMSON REUTERS · 02-07
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire · 02-07
Iterum Therapeutics PLC expected to post a loss of 21 cents a share - Earnings Preview
Reuters · 02-05
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
GlobeNewswire · 01-31
Iterum Therapeutics Plc Files for Offering of up to $25 Mln of Ordinary Shares - SEC Filing
THOMSON REUTERS · 2024-12-10
Iterum Therapeutics Shares Rise After Regaining Compliance With Nasdaq's Listing Rules
MT Newswires Live · 2024-11-21
Iterum Therapeutics regains full Nasdaq compliance
TIPRANKS · 2024-11-21
Iterum Therapeutics Regains Full Nasdaq Compliance
THOMSON REUTERS · 2024-11-21
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...
GuruFocus.com · 2024-11-15
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...
Iterum Therapeutics PLC reports results for the quarter ended September 30 - Earnings Summary
Reuters · 2024-11-14
Iterum Therapeutics Q3 2024 Adj. EPS $(0.24) Misses $(0.20) Estimate. Cash And Equivalents Of $14.5M
Benzinga · 2024-11-14
Iterum Therapeutics Q3 Adjusted Net Income USD -4.837 Million
THOMSON REUTERS · 2024-11-14
Introduction
Company Name.
Iterum Therapeutics Plc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App